Gilead Reports final analysis Data for Tezepelumab in Thyroid eye disease

Gilead today announced final analysis results for Tezepelumab in patients with Thyroid eye disease. The study demonstrated that Tezepelumab achieves primary endpoint with statistical significance compared to standard of care or placebo. These results provide important insights into the treatment of Thyroid eye disease and support the continued development of Tezepelumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tezepelumab was consistent with previous observations, with no new safety signals identified.